Article
The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.
Medical oncology (Northwood, London, England) - 1 Mar 2015
Zhang Yaxiong, Fang Wenfeng, Yan Yue, Wang Mengyao, Kang Shiyang, Sheng Jin, Zhan Jianhua, Chen Nan, Hong Shaodong, Yang Yunpeng, Ma Yuxiang, He Dacheng, Qin Tao, Zhou Ting, Tang Yanna, He Xiaobo, Liang Wenhua, Zhang Li
Abstract excerpt
Non-small cell lung cancer (NSCLC) patients harboring KRAS mutation were associated with worse prognosis and lower response to epidermal growth factor receptor (EGFR) target therapy than those with wild-type tumors. However, whether the underlying biological differences are associated with the efficacy of cytotoxic chemotherapy in advanced NSCLC patients remained controversial. We searched electronic databases...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.